Fuyuan Pharmaceutical announced that its wholly-owned subsidiary, Anhui Fuyuan, recently received the “Drug Supplement Application Approval Notice” for bifonazole solution issued by the State Drug Administration and approved the supplementary application for the drug to increase specifications by 1%, which is deemed to have passed the consistency evaluation. As of the announcement date, the total R&D investment for this specification was 180,000 yuan. In 2025, sales of bifonazole solutions in China's three major terminals and six major markets will be about 350 million yuan. This approval will enrich the company's product line, but drug sales are affected by policy, market and other factors, and there is uncertainty.

Fuyuan Pharmaceutical announced that its wholly-owned subsidiary, Anhui Fuyuan, recently received the “Drug Supplement Application Approval Notice” for bifonazole solution issued by the State Drug Administration and approved the supplementary application for the drug to increase specifications by 1%, which is deemed to have passed the consistency evaluation. As of the announcement date, the total R&D investment for this specification was 180,000 yuan. In 2025, sales of bifonazole solutions in China's three major terminals and six major markets will be about 350 million yuan. This approval will enrich the company's product line, but drug sales are affected by policy, market and other factors, and there is uncertainty.